Explore DexCom, Inc.'s Q3 2025 financial performance with $1.2B revenue and $283.8M net income. Strong growth trends and a 'Buy' recommendation make this report a must-read.
Explore DexCom, Inc.'s Form 8-K filed on Oct 30, 2025, detailing crucial shareholder information and stock updates.
Explore Dexcom, Inc.'s recent 8-K report from October 24, 2025, detailing significant corporate updates and compliance with SEC regulations.
Discover critical insights from Dexcom, Inc.'s 8-K filing on September 14, 2025, detailing significant events affecting their common stock.
Explore Dexcom's Q2 2025 financial report highlighting 15.2% revenue growth and a $750M share repurchase plan. A compelling buy for investors in the CGM market.
Explore Dexcom's latest Form 8-K filing detailing significant corporate updates and stock info as of July 25, 2025. Stay informed on DXCM's market activities.
Explore Dexcom, Inc.'s 8-K report detailing significant events and stock performance as of May 9, 2025. Get insights on DXCM and corporate developments impacting investors.
Explore Dexcom, Inc.'s recent 8-K/A filing detailing critical updates from March 6, 2025, vital for investors and market analysts.
Explore Dexcom, Inc.'s latest 8-K report filed on May 8, 2025, revealing vital updates in the medical tech sector. Stay informed on significant events affecting DXCM stock.
Explore Dexcom, Inc.'s latest 8-K filing details, stock info, and significant updates for May 1, 2025. Essential for investors and stakeholders.
Explore Dexcom's Q1 2025 financial performance with a 12.5% revenue growth but declining net income. Key insights for investors on profitability and future strategies.
Explore Dexcom, Inc.'s 8-K report filed on May 1, 2025, detailing company info, stock data, and compliance with SEC regulations.